REGENXBIO Inc. financial data

Symbol
RGNX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
9804 Medical Center Drive, Rockville, Maryland
Fiscal year end
December 31
Former names
ReGenX Biosciences, LLC (to 11/7/2013)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 304 % -14.5%
Debt-to-equity 71.2 % +24.7%
Return On Equity -70.7 % -42.3%
Return On Assets -41.3 % -30.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.3 M shares +13.3%
Common Stock, Shares, Outstanding 49 M shares +12.8%
Entity Public Float 805 M USD -18.3%
Common Stock, Value, Issued 5 K USD +25%
Weighted Average Number of Shares Outstanding, Basic 45.7 M shares +5.25%
Weighted Average Number of Shares Outstanding, Diluted 45.7 M shares +5.25%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 86.7 M USD -20.9%
Research and Development Expense 229 M USD -6.83%
General and Administrative Expense 84.2 M USD -1.69%
Costs and Expenses 353 M USD -3.97%
Operating Income (Loss) -266 M USD -3.23%
Nonoperating Income (Expense) 5.53 M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -264 M USD +5.98%
Income Tax Expense (Benefit) -152 K USD -81%
Net Income (Loss) Attributable to Parent -260 M USD +3.75%
Earnings Per Share, Basic -5.87 USD/shares +5.93%
Earnings Per Share, Diluted -5.87 USD/shares +5.93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 113 M USD +61.2%
Marketable Securities, Current 226 M USD -13.8%
Cash, Cash Equivalents, and Short-term Investments 381 M USD -19.6%
Accounts Receivable, after Allowance for Credit Loss, Current 15.8 M USD -16.1%
Other Assets, Current 27.3 M USD +18.7%
Assets, Current 395 M USD +1.6%
Property, Plant and Equipment, Net 128 M USD -9.83%
Operating Lease, Right-of-Use Asset 57.6 M USD -9.68%
Other Assets, Noncurrent 4.22 M USD -49.1%
Assets 629 M USD -15.9%
Accounts Payable, Current 31.4 M USD +34.7%
Employee-related Liabilities, Current 8.09 M USD -6.83%
Contract with Customer, Liability, Current 13 K USD -99%
Liabilities, Current 110 M USD -1.92%
Operating Lease, Liability, Noncurrent 80.2 M USD -7.83%
Other Liabilities, Noncurrent 3.49 M USD -41.8%
Liabilities 239 M USD -15.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.23 M USD +72.2%
Retained Earnings (Accumulated Deficit) -768 M USD -51.2%
Stockholders' Equity Attributable to Parent 391 M USD -16%
Liabilities and Equity 629 M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.5 M USD +31.5%
Net Cash Provided by (Used in) Financing Activities 121 M USD
Net Cash Provided by (Used in) Investing Activities 13.2 M USD -79.1%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 49 M shares +12.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 78.5 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 115 M USD +59.5%
Deferred Tax Assets, Valuation Allowance 280 M USD +32.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 324 M USD +24.9%
Operating Lease, Liability 89.3 M USD -5.81%
Payments to Acquire Property, Plant, and Equipment 557 K USD -88.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -252 M USD +6.74%
Lessee, Operating Lease, Liability, to be Paid 122 M USD -8.02%
Property, Plant and Equipment, Gross 189 M USD +1%
Operating Lease, Liability, Current 7.07 M USD +12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.8 M USD +3.94%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.9 M USD +5.33%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33 M USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6 M USD +1.43%
Deferred Tax Assets, Operating Loss Carryforwards 61.9 M USD +143%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -152 K USD -81%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 100 K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10 M USD -19.2%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) -152 K USD -74.7%
Current Federal Tax Expense (Benefit) 3 K USD -99.9%
Deferred Tax Assets, Net of Valuation Allowance 43.3 M USD -9.91%
Share-based Payment Arrangement, Expense 38.7 M USD -6.14%
Interest Expense 6.08 M USD -69.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%